Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Sunitinib |
| Synonyms | |
| Therapy Description |
Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sunitinib | Sutent | SU011248 | CSF1R Inhibitor 23 FLT3 Inhibitor 54 KIT Inhibitor 50 PDGFR Inhibitor (Pan) 27 RET Inhibitor 39 VEGFR2 Inhibitor 35 | Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT V559D KIT A829P | Advanced Solid Tumor | no benefit | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792). | 24205792 |
| Unknown unknown | glioblastoma multiforme | no benefit | Sunitinib | Phase II | Actionable | In multiple Phase II clinical trials, Sutent (sunitinib) failed to demonstrate any benefit in patients with glioblastoma with or without concurrent bevacizumab treatment (PMID: 24424564, PMID: 23086433). | 23086433 24424564 |
| KIT V560_L576del KIT V654A | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). | 25239608 |
| KIT V560_Y578del KIT V654A | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Sutent (sunitinib) inhibited growth of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT V654A in culture, and inhibited tumor growth in cell line xenograft models (PMID: 32350132). | 32350132 |
| KIT exon9 | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). | 25239608 |
| KIT V560_Y578del KIT A829P | gastrointestinal stromal tumor | decreased response | Sunitinib | Preclinical | Actionable | In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). | 25239608 |
| KIT N822K | acute myeloid leukemia | predicted - sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated increased sensitivity to Sutent (sunitinib) compared to cells with wild-type KIT, resulting in increased inhibition of colony formation, and induction of cell-cycle arrest, apoptosis, and autophagy in culture (PMID: 31217744). | 31217744 |
| KIT N822K | acute myeloid leukemia | predicted - sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 31085175). | 31085175 |
| KIT W557_K558del KIT T670I | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). | 25239608 |
| KIT W557_K558del KIT D816G | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
| KIT exon 11 del KIT D816E | gastrointestinal stromal tumor | decreased response | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E demonstrated reduced response to growth inhibition by Sutent (sunitinib) compared to cells harboring KIT exon 11 deletion alone in culture (PMID: 31085175). | 31085175 |
| FLT3 exon 14 ins FLT3 Y842C | acute myeloid leukemia | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Sutent (sunitinib) in culture (Blood 2009 114:3776). | detail... |
| KIT exon 11 del KIT T670I | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I in culture (PMID: 31085175). | 31085175 |
| KDR act mut | bladder urothelial carcinoma | predicted - sensitive | Sunitinib | Phase II | Actionable | In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593). | 20142593 |
| KIT V560_Y578del KIT T670I | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508). | 31205508 |
| KIT V560_Y578del KIT T670I | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). | 25239608 |
| PDGFRA V561D PDGFRA D842V | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458). | 18955458 |
| KIT D816Y | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792). | 24205792 |
| KIT A502_Y503dup | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| KIT P551_E554del | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Sutent (sunitinib) in culture (PMID: 25239608). | 25239608 |
| FLT3 exon 14 ins FLT3 A627P | hematologic cancer | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing FLT3 ITD and FLT3 A627P were resistant to treatment with Sutent (sunitinib) in culture (PMID: 22858906). | 22858906 |
| KIT V559_V560del | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture (PMID: 24205792). | 24205792 |
| KIT W557_K558del KIT N822K | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
| ASXL1 mutant | acute myeloid leukemia | predicted - resistant | Sunitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived acute myeloid leukemia cells harboring ASXL1 mutations were resistant to Sutent (sunitinib) in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323). | detail... |
| KIT exon11 | gastrointestinal stromal tumor | decreased response | Sunitinib | Clinical Study - Cohort | Actionable | In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734). | 26772734 |
| PDGFRA Y288C | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923). | 30389923 |
| KDR D717V | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655). | 19723655 |
| Unknown unknown | ovarian cancer | not applicable | Sunitinib | Phase Ib/II | Actionable | In a Phase II trial, Sutent (sunitinib) treatment in ovarian cancer patients resulted in an increased PFS and a response rate of 16.7% (6/36) in those that received Sutent (sunitinib) continuously and a a response rate of 5.4% (2/37) in those that received the drug non-continuously (PMID: 22377563, PMID: 24070205). | 22377563 24070205 |
| KIT W557_K558del KIT V654A | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Pdx | Actionable | In a preclinical study, Sutent (sunitinib) inhibited tumor growth in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT V654A, which was established from a patient who did not respond to Gleevec (imatinib) treatment (PMID: 32350132). | 32350132 |
| KIT V560D | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). | 25239608 |
| KIT D816V | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557). | 19164557 |
| KIT D816V | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792). | 24205792 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Sunitinib | Phase III | Actionable | In a Phase III trial, Sutent (sunitinib) as maintenance therapy resulted in improved progression free survival (4.3 vs 2.6 months) but not overall survival (11.7 vs 12.1 months) compared to placebo in patients with stage IIIB/IV non-small cell lung cancer (PMID: 28161554). | 28161554 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Sunitinib | Phase II | Actionable | In a Phase II trial, Sutent (sunitinib) treatment in non-small cell lung cancer patients resulted in an objective response rate of 11.1% (7/63), stable disease in 28.6% (18/63), and a PFS of 12 weeks and OS of 23.4 weeks (PMID: 18235126). | 18235126 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Sunitinib | Phase II | Actionable | In a Phase II trial, Sutent (sunitinib) treatment resulted in an objective response rate of 8% (1/13, partial response) and stable disease as the best response in 69% (9/13) of non-small cell lung carcinoma patients (PMID: 32312893; NCT01829217). | 32312893 |
| KIT A829P | melanoma | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040). | 23582185 25594040 |
| KIT V560G KIT D816V | mast cell neoplasm | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Sutent (sunitinib) in culture (PMID: 31085175). | 31085175 |
| KDR over exp | breast cancer | predicted - resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623). | 28011623 |
| KIT W557_K558del | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). | 25239608 |
| Unknown unknown | malignant glioma | not applicable | Sunitinib | Phase II | Actionable | In a Phase II clinical trial, Sutent (sunitinib) was well-tolerated in young patients with high grade glioma, but did not demonstrate sufficient anti-tumor activity as a single agent, with no patients achieving a sustained objective response (PMID: 27109549). | 27109549 |
| Unknown unknown | malignant glioma | not applicable | Sunitinib | Preclinical | Actionable | In a preclinical study, Sutent (sunitinb) induced cell death and decreased proliferation of glioma cells in culture (PMID: 25458015). | 25458015 |
| KIT W557_K558del KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). | 25239608 |
| Unknown unknown | pancreatic endocrine carcinoma | not applicable | Sunitinib | FDA approved | Actionable | In a Phase III clinical trial that supported FDA approval, Sutent (sunitinib) demonstrated safety and improved progression free survival in patients with pancreatic neuroendocrine tumors (PMID: 21306237). | 21306237 detail... |
| KIT D816H | Advanced Solid Tumor | predicted - sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT D816H were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib) (PMID: 24205792). | 24205792 |
| KIT V560_Y578del KIT D816E | gastrointestinal stromal tumor | decreased response | Sunitinib | Preclinical | Actionable | In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). | 25239608 |
| KIT N822K | Advanced Solid Tumor | predicted - sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT N822K were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib), demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| PDGFRA amp | lung non-small cell carcinoma | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796). | 19366796 |
| FLT3 exon 14 ins FLT3 F691I | Advanced Solid Tumor | decreased response | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356). | 23392356 |
| KIT D816Y | mast cell neoplasm | decreased response | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) demonstrated reduced response to growth inhibition by Sutent (sunitinib) compared to GIST cells harboring KIT exon 11 deletion in culture (PMID: 31085175). | 31085175 |
| Unknown unknown | endometrial cancer | not applicable | Sunitinib | Phase II | Actionable | In Phase II clinical trials, Sutent (sunitinib) demonstrated efficacy in patients with metastatic or recurrent endometrial carcinoma (PMID: 24882554). | 24882554 |
| KIT K550_W557del | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). | 25239608 |
| KIT K642E | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor (GIST) cell line and primary GIST patient-derived cells harboring KIT K642E in culture (PMID: 31205508). | 31205508 |
| KIT T670I | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I in culture (PMID: 31205508). | 31205508 |
| Unknown unknown | colon cancer | not applicable | Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Sutent (sunitinib) induced apoptosis in colon cancer cells in culture and in cell line xenograft models (PMID: 22912816). | 22912816 |
| KIT T417_D419delinsI | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Sutent (sunitinib), demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 31205508). | 31205508 |
| KIT V559D KIT T670I | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I and KIT V559D in culture (PMID: 31205508). | 31205508 |
| KIT V559D KIT T670I | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing KIT V559D and KIT T670I were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| KDR act mut | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655). | 19723655 |
| PDGFRA D842V | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923). | 30389923 |
| PDGFRA D842V | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458). | 18955458 |
| Unknown unknown | malignant ependymoma | not applicable | Sunitinib | Phase II | Actionable | In a Phase II clinical trial, Sutent (sunitinib) was well-tolerated in young patients with ependymoma, but did not demonstrate sufficient anti-tumor activity as a single agent, with no patients achieving a sustained objective response (PMID: 27109549). | 27109549 |
| FLT3 exon 14 ins FLT3 A848P | Advanced Solid Tumor | resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356). | 23392356 |
| KIT W557_K558del KIT D816H | Advanced Solid Tumor | decreased response | Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608). | 25239608 |
| Unknown unknown | renal cell carcinoma | not applicable | Sunitinib | FDA approved | Actionable | In a Phase III clinical trial that supported FDA approval, treatment with Sutent (sunitinib) resulted in improved median progression free survival (47.3 weeks) and objective response rate (27.5%) in patients with renal cell carcinoma (PMID: 19707433). | 19707433 detail... |
| Unknown unknown | renal cell carcinoma | not applicable | Sunitinib | Phase III | Actionable | In a Phase III clinical trial, treatment with Sutent (sunitinib) resulted in prolonged disease free survival (HR = 0.761) compared to placebo in post-nephrectomy patients with renal cell carcinoma (ESMO 2016 Congress in Copenhagen, Abstract LBA11_PR). | detail... |
| KIT W557_K558del KIT A829P | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
| KIT exon11 KIT T670I | gastrointestinal stromal tumor | predicted - sensitive | Sunitinib | Preclinical - Pdx | Actionable | In a preclinical study, Sutent (sunitinib) inhibited Kit signaling, resulted in 86.7% tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343). | 29100343 |
| FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs | adenoid cystic carcinoma | no benefit | Sunitinib | Case Reports/Case Series | Actionable | In a clinical case study, Sutent (sunitinib) treatment resulted in rapid disease progression in a patient with metastatic adenoid cystic carcinoma harboring co-occurring NOTCH1 L1600Q and S2467fs, and acquired FBXW7 W606* and NOTCH1 V1721G (PMID: 27870570). | 27870570 |
| KIT exon9 | gastrointestinal stromal tumor | predicted - sensitive | Sunitinib | Clinical Study - Cohort | Actionable | In a retrospective analysis, GIST patients with KIT exon 9 mutations showed improved progression-free survival (PFS), overall survival, and objective response rate (ORR) compared to patients with exon 11 mutations, with a median PFS of 12.3 months vs. 7.0 months, and an ORR of 19% (8/42) vs. 6% (9/143) following treatment with Sutent (sunitinib) (PMID: 26772734). | 26772734 |
| Unknown unknown | gastrointestinal stromal tumor | not applicable | Sunitinib | FDA approved | Actionable | In a Phase III clinical trial that supported FDA approval, treatment with Sutent (sunitinib) improved median progression free survival to 27.3 weeks in GIST patients (PMID: 17332278). | 17332278 detail... |
| FLT3 exon 14 ins FLT3 F621L | acute myeloid leukemia | decreased response | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated a decreased response to Sutent (sunitinib) in culture when compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776). | detail... |
| KIT I571_D579dup | Advanced Solid Tumor | predicted - resistant | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Sutent (sunitinib) in culture (PMID: 24205792). | 24205792 |
| KIT H697Y | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435). | 19861435 |
| KIT V560_Y578del | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508). | 31205508 |
| KIT A502_Y503dup KIT D820E | gastrointestinal stromal tumor | predicted - resistant | Sunitinib | Preclinical - Pdx | Actionable | In a preclinical study, Sutent (sunitinib) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal (26.2%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343). | 29100343 |
| KIT V559D KIT Y823D | Advanced Solid Tumor | no benefit | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing KIT Y823D and KIT V559D were insensitive to Sutent (sunitinib) in culture and in mouse models (PMID: 24205792). | 24205792 |
| PDGFRA V561D | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to Sutent (sunitinib) in culture, resulting in decreased cell proliferation (PMID: 30389923). | 30389923 |
| KIT T670I | melanoma | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040). | 23582185 25594040 |
| VHL mutant | renal cell carcinoma | predicted - sensitive | Sunitinib | Phase I | Actionable | In a Phase I trial, 33% (6/18) of renal cell carcinoma patients harboring a VHL mutation, as determined from archived patient specimens, demonstrated a partial response when treated with Sutent (sunitinib) (PMID: 22105611). | 22105611 |
| KIT W557_K558del KIT D820G | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
| RET rearrange | lung non-small cell carcinoma | predicted - sensitive | Sunitinib | Clinical Study | Actionable | In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912). | 28447912 |
| RET rearrange | lung non-small cell carcinoma | predicted - sensitive | Sunitinib | Clinical Study - Cohort | Actionable | In a Phase II trial, Sutent (sunitinib) treatment resulted in no objective responses (n=7) and a stable disease in 71% (5/7) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 32312893; NCT01829217). | 32312893 |
| KIT V560D KIT D820A | gastrointestinal stromal tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458). | 18955458 |
| KIT V559D | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT V559D were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792). | 24205792 |
| KIT W557_K558del KIT D820A | Advanced Solid Tumor | resistant | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
| KIT V559D KIT N822K | Advanced Solid Tumor | no benefit | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing KIT N822K and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792). | 24205792 |
| KIT V560del | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435). | 19861435 |
| KIT exon 11 del | gastrointestinal stromal tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175). | 31085175 |
| Unknown unknown | lung small cell carcinoma | not applicable | Sunitinib | Phase II | Actionable | In a Phase II trial, Sutent (sunitinib) treatment in small cell lung cancer patients resulted in a partial response of 11% (1/9) and stable disease in 30% (3/9) (PMID: 26716400). | 26716400 |
| KIT V560G | mast cell neoplasm | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175). | 31085175 |
| KDR A1065T | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655). | 19723655 |
| KIT V559D KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells co-expressing KIT V559D and KIT V654A were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| KIT V559D KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A and KIT V559D in culture (PMID: 31205508). | 31205508 |
| KIT K558delinsNP | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). | 25239608 |
| FLT3 exon 14 ins NPM1 mut | acute myeloid leukemia | predicted - sensitive | Sunitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Sutent (sunitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). | 30333627 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT03091192 | Phase III | Sunitinib Savolitinib | Savolitinib vs. Sunitinib in MET-driven PRCC. | Active, not recruiting |
| NCT03035630 | Phase II | Avelumab Sunitinib | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Withdrawn |
| NCT02811861 | Phase III | Everolimus + Lenvatinib Sunitinib Lenvatinib + Pembrolizumab | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Active, not recruiting |
| NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Completed |
| NCT01396148 | Phase II | Sunitinib | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | Completed |
| NCT01525550 | FDA approved | Sunitinib | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | Completed |
| NCT01026337 | Phase 0 | Sunitinib | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | Completed |
| NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting |
| NCT01984242 | Phase II | Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed |
| NCT00747305 | Phase I | Sunitinib | Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery | Terminated |
| NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated |
| NCT02465060 | Phase II | Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting |
| NCT01370109 | Phase I | Sunitinib | Cardiovascular Effects of Sunitinib Therapy (CREST) | Completed |
| NCT01164228 | Phase II | Sunitinib Gemcitabine | Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | Active, not recruiting |
| NCT02060370 | Phase II | Sunitinib | Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | Completed |
| NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting |
| NCT03541902 | Phase II | Cabozantinib Sunitinib | Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | Recruiting |
| NCT00843037 | Phase II | Sunitinib | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | Active, not recruiting |
| NCT02853331 | Phase III | Axitinib + Pembrolizumab Sunitinib | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | Active, not recruiting |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Recruiting |
| NCT01621568 | Phase II | Sunitinib | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | Active, not recruiting |
| NCT01582204 | Phase I | Pazopanib Sunitinib | Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting |
| NCT01603004 | Phase I | Everolimus Sunitinib | Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors | Completed |
| NCT01517243 | Phase II | Temsirolimus Sunitinib | Phase II Study of Alternating Sunitinib and Temsirolimus | Active, not recruiting |
| NCT01499121 | Phase II | Sunitinib | Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule | Completed |
| NCT00794950 | Phase II | Sunitinib | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma | Completed |
| NCT01582672 | Phase III | Sunitinib | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) | Terminated |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Recruiting |
| NCT03641326 | Phase II | Sunitinib | Sunitinib in Sarcomas of the Central Nervous System | Recruiting |
| NCT01391962 | Phase II | Sunitinib Cediranib | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | Active, not recruiting |
| NCT00702884 | Phase II | Sunitinib | Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer | Completed |
| NCT02432846 | Phase II | Sunitinib | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA) | Completed |
| NCT03141177 | Phase III | Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab | A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Active, not recruiting |
| NCT03673501 | Phase III | Sunitinib Ripretinib | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue) | Recruiting |
| NCT02761057 | Phase II | Savolitinib Cabozantinib Crizotinib Sunitinib | Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Active, not recruiting |
| NCT00981890 | Phase I | Sunitinib | Stereotactic Radiosurgery With Sunitinib for Brain Metastases | Active, not recruiting |
| NCT02420821 | Phase III | Bevacizumab Sunitinib Atezolizumab | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Active, not recruiting |
| NCT00463060 | Phase Ib/II | Sunitinib | Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer | Completed |
| NCT00717587 | Phase II | Sunitinib Girentuximab Motexafin gadolinium | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | Unknown status |
| NCT03109015 | Phase II | Sunitinib | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET) | Completed |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Recruiting |
| NCT02164240 | Phase I | Sunitinib Regorafenib | Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST | Active, not recruiting |
| NCT02684006 | Phase III | Avelumab + Axitinib Sunitinib | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | Active, not recruiting |
| NCT02483247 | Phase Ib/II | Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab BBI503 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | Active, not recruiting |
| NCT01829217 | Phase II | Sunitinib | Sunitinib in Never-Smokers With Lung Adenocarcinoma | Completed |
| NCT00375674 | Phase III | Sunitinib | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer (S-TRAC) | Completed |
| NCT02779283 | Phase I | Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed |
| NCT01099423 | Phase III | Sunitinib | Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer | Unknown status |
| NCT02068586 | Phase II | Valproic acid Sunitinib | Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma | Recruiting |
| NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Active, not recruiting |
| NCT02231749 | Phase III | Ipilimumab + Nivolumab Sunitinib | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Active, not recruiting |
| NCT01620216 | Phase II | Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib | Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients | Unknown status |
| NCT01014065 | Phase II | Sunitinib | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) | Completed |
CKB BOOST